CClinicalTrials.gg
Status unknownNCT03953716Updated Jun 25, 2019

Traditional Chinese Medicine, Western Medicine and Low-level Light Therapy(LLLT) for Primary Dysmenorrhea(PD)

A Phase 4 interventional study of low level light therapy and DING KUN DAN in Primary Dysmenorrhea, Traditional Chinese Medicine and Light, sponsored by Peking Union Medical College Hospital. Status unknown at 1 site in China. Open to female participants aged 16 Years to 35 Years. Per ClinicalTrials.gov, last updated 2019-06-25.

Sponsored by Peking Union Medical College Hospital · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jun 2019), so the status shown — last known as Recruiting — may be out of date.
Phase
Phase 4
Study type
Interventional
Enrollment
480
Allocation
Randomized
Ages
16 Years to 35 Years
Sex
Female
01

Study summary

To observe the clinical efficacy and safety of three methods for the treatment of primary dysmenorrhea. Establish an integrated biomarker index system for the evaluation of the efficacy of traditional Chinese medicine, western medicine and Low-level Light Therapy for the treatment of primary dysmenorrhea, and further explore the mechanism and therapeutic material basis of the three treatment methods for the treatment of primary dysmenorrhea

Read the detailed description

480 women clinically diagnosed of primary dysmenorrhea will be enrolled from nationwide multi-centers. Blood samples were collected from 480 patients before and after treatment (1 experimental group, 3 control groups, treatment cycle of 3 menstrual cycles, follow-up cycle of 5 menstrual cycles), Metabonomics study, and integration of clinical sample information (Serum biochemical indicators, imaging indicators, etc.), through bioinformatics to establish a comprehensive biomarker index system for the evaluation of the efficacy of traditional Chinese medicine, Western medicine and Low-level Light Therapy instrument Methods for the treatment of primary dysmenorrhea and its therapeutic basis.

02

Conditions studied

  • Primary Dysmenorrhea
  • Traditional Chinese Medicine
  • Light

Browse trials for

Keywords

  • Primary Dysmenorrhea
  • traditional Chinese medicine
  • low-level light therapy
03

In context

Dysmenorrhea

398 studies on the registry are indexed under Dysmenorrhea; 96 are open to participants now.

This study's planned enrollment of 480 is above the median of 60 across 333 interventional studies indexed under Dysmenorrhea.

Browse Dysmenorrhea studies →

Lead sponsor

Peking Union Medical College Hospital is the lead sponsor of 1,115 studies on the registry; 463 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  1. Female (16-35 years old);
  2. regular Menstruation (cycle 21-35 days, menstrual period 3-7 days);
  3. Be clinically diagnosed with primary dysmenorrhea;
  4. Be willing to participate in the whole process of the research in 5 consecutive menstrual cycles.

Exclusion criteria

Exclusion Criteria:

  1. irregular menstruation affecting the treatment and efficacy judgment;
  2. Patients with secondary dysmenorrhea;
  3. Those who have used related drugs in the past 3 months;
  4. Abuse or dependence on substances (alcohol or medicine) in the past 3 months; heavy smokers (smokers who smoke 20 or more cigarettes per day);
  5. Those who have severe or unstable physical illnesses, related to liver, kidney, gastrointestinal tract, cardiovascular, respiratory, endocrine, nervous, immune or blood systems, neuropsychiatric systems and so on;
  6. Lactating or pregnant women, or women within 1 year after delivery;
  7. Those who are allergic to the test drug or light, have contraindications for Marvelon and Ding kun dan;
  8. Have a history of thromboembolic disease or a tendency to thrombosis;
  9. one month before joining in this study (first interview), Who participated in another clinical trial;
  10. Those who meet the inclusion criteria, fail to follow the doctor's advice so that we cannot judge the curative effect ,the incomplete data cannot be evaluated.
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
480 participants (estimated)

Study arms

  • Experimental
    DING KUN DAN

    DING KUN DAN,3.5g BID for 10 days (starting 3-5 days before menstruation) \*3 menstrual cycle

    Drug: DING KUN DAN

  • Placebo comparator
    Simulated drug of DING KUN DAN

    Simulated drug of DING KUN DAN,3.5g BID for 10 days (starting 3-5 days before menstruation) \*3 menstrual cycle

    Drug: Simulated drug of DING KUN DAN

  • Experimental
    low level light therapy

    Start using low level light therapy after the menstrual period, once a day, every 20 minutes \* 5 days ( one treatment cycle), start the next course at intervals of 2 days until the next menstruation

    Device: low level light therapy

  • Active comparator
    Marvelon

    1 pill QD\*21 days (starting on the 5th day of menstruation, continuing the next cycle after 1 week of withdrawal) \*3 menstrual cycle

    Drug: Marvelon

Interventions

  • Devicelow level light therapy

    Start using low level light therapy after the menstrual period, once a day, every 20 minutes \* 5 days ( one treatment cycle), start the next course at intervals of 2 days until the next menstruation

  • DrugDING KUN DAN

    DING KUN DAN,3.5g BID for 10 days (starting 3-5 days before menstruation) \*3 menstrual cycle

  • DrugSimulated drug of DING KUN DAN

    Simulated drug of DING KUN DAN,3.5g BID for 10 days (starting 3-5 days before menstruation) \*3 menstrual cycle

  • DrugMarvelon

    Marvelon 1 pill QD\*21 days (starting on the 5th day of menstruation, continuing the next cycle after 1 week of withdrawal) \*3 menstrual cycle

06

What researchers measure

Primary outcomes

  1. Visual Analogue Scale,VAS

    Visual Analogue Scale/Score (VAS): Draw a 10 cm horizontal line on the paper. The degree of pain is indicated by the line segment,One end of the horizontal line is 0, indicating no pain; the other end is 10, indicating severe pain; the middle part indicates different degrees of pain(the mild pain is 1-3, the moderate is 4-6, the severity is 7-9),The patient chooses the value that can represent the degree of pain.

    Time frame: about 30 days

Secondary outcomes

  1. Short-form McGill Pain Questionnaire-2, SF-MPQ-2

    Short-form McGill Pain Questionnaire-2(SF-MPQ-2), By this scale, we can evaluate the different types of pain and the emotional effects of PD. It has 22 entries. These 22 entries include: Jumping pain, shooting pain, knife-like pain, sharp pain, cramping and dragging pain, constant biting pain, hot burning pain, sore pain, falling pain, slightly pressing pain, tearing pain, exhaustion - weakness, disgusting, fear, Torture - punishment, electric shock, cold pain, puncture pain, pain caused by gentle touch, itching, pin and needles pain, numbness. Each entry scored "0\~10" points, the minimum score is 0,the maximum score is 10,a total of 11 levels. "0" indicates that never have this pain or symptom, "10" represents that this pain or feel is severe,"1-9" indicates different degrees of this type of pain or symptom. At last, Calculate the total score of all 22 items.

    Time frame: about 30 days

  2. the COX menstrual symptom scale,CMSS

    the COX menstrual symptom scale (CMSS), this score evaluate the level of PD from the two aspects of dysmenorrhea symptoms: the duration and severity , It has 17 entries including: cramps , nausea, vomiting, loss of appetite, headaches, backaches, leg aches, dizziness, weakness, diarrhea, facial blemishes, abdominal pain, flushing, general aching, depression, irritability, nervousness. Each entry scored "0\~4" points, different score represents different duration or severity of corresponding symptoms : for the duration, 0 indicates never have this symptom, 1 means lasting less 3 hours, 2 means lasting 3\~7 hours, 3 means 7\~24 hours, 4 means more than 24 hours. as for the severity,0 indicates no pain; the mild is 1, the moderate is 2, the severity is 3, the extreme severity is 4. Then, Calculate the score of the duration and severity of all 17 items respectively, lastly, sum the total score of the duration and severity.

    Time frame: about 30 days

  3. Menstrual flow graph analysis table

    Through this form, we can know about the menstrual period and menstrual flow before and after treatment: Mild: blood stained area ≤ 1/3 of the entire sanitary napkin area; Moderate: blood stained area accounts for 1/3-3/5 of the entire sanitary napkin area; Severe: The blood stained area is basically the entire sanitary napkin. Blood clot area \<1 dollar coin, which is a small blood clot; The blood clot area is ≥1 yuan coin, which is a large blood clot. fill in the number of sanitary napkins used in the appropriate space according to the degree of blood stain or the amount of the blood clot on each sanitary napkin discarded.

    Time frame: about 30 days

  4. Uterine artery Pulsation index

    Determination of uterine artery hemodynamics, can reflect the state of uterine blood circulation, the higher the uterine artery pulsation index, the decrease of blood flow, the lower the uterine artery pulsation index, the increase of blood flow or neo-vascularization

    Time frame: 3 months

  5. Uterine artery Resistance index

    Determination of uterine artery hemodynamics, can reflect the state of uterine blood circulation, the higher the uterine artery resistance index, indicating less blood supply to uterine, the lower the uterine artery resistance index, the increased blood supply to uterine.

    Time frame: 3 months

  6. Uterine artery Systolic peak and diastolic peak ratio

    The greater the ratio of uterine artery systolic peak to diastolic peak, indicating that the end-diastolic blood flow velocity is small and the peripheral resistance is large; conversely, the blood flow velocity is large and the peripheral resistance is small.

    Time frame: 3 months

07

Study locations

1 of 1 sites recruiting
  • Xiao MA
    Beijing, Beijing 100000, China
    Recruiting
08

References and documents

Publications

  • Zhu S, Ma X, Ding X, Gan J, Deng Y, Wang Y, Sun A. Comparative evaluation of low-level light therapy and ethinyl estradiol and desogestrel combined oral contraceptive for clinical efficacy and regulation of serum biochemical parameters in primary dysmenorrhoea: a prospective randomised multicentre trial. Lasers Med Sci. 2022 Jun;37(4):2239-2248. doi: 10.1007/s10103-021-03490-z. Epub 2022 Jan 14. PubMed 35028764 ↗

Individual participant data

Plan to share: Yes — Network platform, and the website will be attached later.

Supporting information: Study protocol, Icf, Csr, Analytic code

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 25, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03953716
Lead sponsor
Peking Union Medical College Hospital
Responsible party
Aijun Sun (Professor, Peking Union Medical College Hospital) — Principal investigator
First posted
May 17, 2019
Start date
Jun 22, 2019 (estimated)
Primary completion
Jun 30, 2020 (estimated)
Completion
Jun 30, 2020 (estimated)
Last update
Jun 25, 2019

Study contacts

Xiao Ma, B.S.
Contact
doctor_max@sina.com
18810711533 ext. #86
Aijun SUN, MD
principal investigator · Peking Union Medical College Hospital, Chinese Academy of Medicine Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion